Association between Immunophenotypic Parameters and Molecular Alterations in Acute Myeloid Leukemia.

Autor: Pessoa FMCP; Department of Medicine, Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza 60430-275, CE, Brazil., Machado CB; Department of Medicine, Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza 60430-275, CE, Brazil., Barreto IV; Department of Medicine, Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza 60430-275, CE, Brazil., Sampaio GF; Unichristus University Center, Faculty of Biomedicine, Fortaleza 60430-275, CE, Brazil., Oliveira DS; Department of Hematology, Fortaleza General Hospital (HGF), Fortaleza 60150-160, CE, Brazil., Ribeiro RM; Department of Hematology, Fortaleza General Hospital (HGF), Fortaleza 60150-160, CE, Brazil., Lopes GS; Department of Hematology, César Cals General Hospital, Fortaleza 60015-152, CE, Brazil., de Moraes MEA; Department of Medicine, Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza 60430-275, CE, Brazil., de Moraes Filho MO; Department of Medicine, Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza 60430-275, CE, Brazil., de Souza LEB; Center for Cell-Based Therapy, Regional Blood Center of Ribeirão Preto, University of São Paulo, São Paulo 14040-900, SP, Brazil., Khayat AS; Department of Biological Sciences, Oncology Research Center, Federal University of Pará, Belém 66073-005, PA, Brazil., Moreira-Nunes CA; Department of Medicine, Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza 60430-275, CE, Brazil.; Unichristus University Center, Faculty of Biomedicine, Fortaleza 60430-275, CE, Brazil.; Department of Biological Sciences, Oncology Research Center, Federal University of Pará, Belém 66073-005, PA, Brazil.
Jazyk: angličtina
Zdroj: Biomedicines [Biomedicines] 2023 Apr 05; Vol. 11 (4). Date of Electronic Publication: 2023 Apr 05.
DOI: 10.3390/biomedicines11041098
Abstrakt: Acute myeloid leukemia (AML) is a hematologic malignancy that occurs due to alterations such as genetic mutations, chromosomal translocations, or changes in molecular levels. These alterations can accumulate in stem cells and hematopoietic progenitors, leading to the development of AML, which has a prevalence of 80% of acute leukemias in the adult population. Recurrent cytogenetic abnormalities, in addition to mediating leukemogenesis onset, participate in its evolution and can be used as established diagnostic and prognostic markers. Most of these mutations confer resistance to the traditionally used treatments and, therefore, the aberrant protein products are also considered therapeutic targets. The surface antigens of a cell are characterized through immunophenotyping, which has the ability to identify and differentiate the degrees of maturation and the lineage of the target cell, whether benign or malignant. With this, we seek to establish a relationship according to the molecular aberrations and immunophenotypic alterations that cells with AML present.
Databáze: MEDLINE
Externí odkaz: